SGRY VS RETA Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilitySentiment
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilitySentiment

Performance

SGRY
10/100

SGRY returned 4.97% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

RETA
100/100

RETA returned 201.37% in the last 12 months. Based on SPY's performance of -8.69%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

SGRY
61/100

9 analysts offer 12-month price targets for SGRY. Together, they have an average target of 64, the most optimistic target put SGRY at 64 within 12-months and the most pessimistic has SGRY at 64.

RETA
94/100

8 analysts offer 12-month price targets for RETA. Together, they have an average target of 62.67, the most optimistic target put RETA at 115 within 12-months and the most pessimistic has RETA at 27. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Technicals

SGRY
64/100

SGRY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

RETA
89/100

RETA receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

SGRY
10/100

SGRY has missed earnings 11 times in the last 20 quarters.

RETA
24/100

RETA has missed earnings 4 times in the last 20 quarters.

Profit

SGRY
61/100

Out of the last 20 quarters, SGRY has had 14 profitable quarters and has increased their profits year over year on 7 of them.

RETA
10/100

Out of the last 20 quarters, RETA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SGRY
47/100

SGRY has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

RETA
55/100

RETA has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

Sentiment

SGRY

"Sentiment" not found for SGRY

RETA
68/100

RETA had a bullish sentiment score of 68.36% across Twitter and StockTwits over the last 12 months. It had an average of 25.41 posts, 219.86 comments, and 296.56 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Surgery Partners, Inc. Common Stock Summary

Nasdaq / SGRY
Healthcare
Medical - Care Facilities
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Reata Pharmaceuticals, Inc. Class A Common Stock Summary

Nasdaq / RETA
Healthcare
Biotechnology
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.